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Background: Early screenings involving biomarkers and use of potential disease-modifying 
therapies (DMTs) may have significant humanistic implications for treatment strategies in 
Alzheimer’s disease.
Methods: Markov models simulated transitions of patient cohorts beginning in predementia, 
a hypothetical early stage of Alzheimer’s disease marked by objective cognitive impairment/
memory complaints without functional impairment, and followed for 10 years. Hypothetical 
cohorts of 10,000 patients included those who were treated with standard of care (donepezil) 
upon reaching mild–moderate Alzheimer’s disease, a DMT in predementia, and a DMT in mild-
moderate Alzheimer’s disease. Transition probabilities were based on data from the Alzheimer’s 
Disease Neuroimaging Initiative and published clinical data, and estimated for the hypothetical 
DMT. In each disease stage (predementia, mild, moderate, or severe), time was computed and 
costs were estimated using literature review and published data, and published data provided 
mortality rates. The impact of screening was evaluated using positive predictive value (patients 
identified as predementia truly at risk for transition to dementia).
Results: Earlier treatment yielded modest gains in total life-years; however, the distribution was 
skewed towards milder disease. Assuming a 25% reduction in the annual risk of progression, 
treating predementia patients with DMT increased life-years in predementia to mild states on 
average from 3.2 to 4.2, while life-years spent in moderate-to-severe Alzheimer’s disease decreased 
from 2.6 to 2.2. Average time in the community increased from 4.4 to 5.4 years, while time in 
long-term care declined from 1.3 to 0.9 years. This impact grows as the advantage of the novel 
agent increases. Screening accuracy had significant implications for cost-effectiveness.
Conclusion: If screening can accurately identify predementia patients at risk for progression, 
earlier treatment with DMTs has the potential benefit to patients of prolonging time in milder 
disease, reducing time spent with more severe disease, increasing time in the community, and 
reducing time in long-term care.
Keywords: Alzheimer’s disease, Markov model, disease-modifying therapy, donepezil,   standard 
of care, predementia
Introduction
Alzheimer’s disease is a fatal, neurodegenerative disorder that affects more than five 
million people in the US, mostly the elderly.1 The disease has an estimated worldwide 
prevalence of 30 million people, with an annual incidence of 4.6 million.2 Without 
effective treatment, this number may increase to more than 115 million by 2050.3 
Progression in patients with Alzheimer’s disease typically follows a predictable course 
marked by a decline in behavior and function, leading to loss of independence,   nursing 
home placement, and ultimately death.4 Patients with mild cognitive impairment ClinicoEconomics and Outcomes Research 2011:3 submit your manuscript | www.dovepress.com
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and amyloidopathy are more likely to develop Alzheimer’s 
disease, offering a window for therapeutic interventions that 
may have an impact on disease progression.1,5
The current standard of care for Alzheimer’s disease 
is limited to symptomatic therapies which provide only 
  temporary improvement in cognitive and behavioral 
  symptoms and at best a temporary impact on the progression 
of the underlying pathology of the disease.6 These treatments 
include the cholinesterase inhibitors donepezil, rivastigmine, 
and galantamine, as well as the N-methyl-D-aspartate antago-
nist, memantine.6 The development of disease-modifying 
therapies (DMTs) is ongoing and may provide some hope for 
afflicted individuals.7,8 In addition, new screening paradigms 
are currently being developed with increasingly accurate 
predictability for the progression to dementia in patients 
with Alzheimer’s disease, especially in earlier disease.9–12 
Early screening involving biomarkers, together with the 
use of DMTs, may have significant humanistic implications 
for treatment strategies.9 The purpose of this study was to 
examine the impact of early screening and effective DMT, 
particularly in the area of slowing disease progression, on 
patient outcomes through the course of the disease, survival, 
and independence as captured by time spent in a progressively 
severe disease state and time spent in a home setting versus 
long-term institutional care.
Methods
Model simulations
A Markov model was used to simulate transitions of 
  Alzheimer’s disease patient cohorts beginning in a   predementia 
state (defined by clinical and biomarker criteria postulated 
as part of the Dubois criteria13 involving memory complaint 
plus the presence of a biomarker, such as elevated amyloid 
β or cerebrospinal fluid tau levels) and followed for 10-year 
periods.14 For each endpoint, scenarios were created and run 
using computer simulations. Simulations were performed using 
SAS 9.1 software (SAS Institute Inc, Cary, NC). For these, 
the Markov models used transitions of patient cohorts, with 
estimated transition probabilities based on published clinical 
data15 for patients with mild, moderate, and severe Alzheimer’s 
disease. Data from the Alzheimer’s Disease Neuroimaging 
Initiative16 were used for estimates of progression from prede-
mentia to Alzheimer’s disease and estimates of the impact of the 
hypothetical DMT. For each scenario, hypothetical cohorts of 
10,000 patients were created and then allowed to flow through 
the course of disease from entry. In the model, six-month cycles 
were used to estimate the occurrences of various events, ie, 
disease-state   transition, movement from home to long-term 
care, and mortality. Therefore, at each six-month point, patients 
could remain in the current state of disease, progress to the next 
more severe disease state, or exit the model via death. Time 
in each disease state (predementia, mild, moderate, or severe) 
was computed. This model assumed that all patients are at risk 
to progress, and the relative rate of progression for each indi-
vidual in each cohort was based on the transition probabilities. 
Each state was defined by the Mini Mental State Examination 
range (Table 1).15 Once patients reached a severe Alzheimer’s 
disease state, they were removed from active treatment, whether 
receiving the hypothetical DMT or standard of care. The flow 
of the model is shown in Figure 1.
For the purpose of this exercise, the three   hypothetical 
cohorts of 10,000 patients each were created with the 
  following characteristics: cohort 1 (standard of care), 
Table 1 Definition of disease states for Alzheimer’s disease
Disease state MMSE range
Predementia 26–30
Mild AD 21–25
Moderate AD 10–20
severe AD ,10
Abbreviations: AD, Alzheimer’s disease; MMsE, Mini Mental state Examination.
Death Death Death Death Death
PD PD PD PD PD
P 0
P 0
P 0
P 0
P1 P1 P1 P1
Predementia AD Mild Moderate Moderately
severe Severe
Figure 1 Model flow. Transition probabilities: P0, probability of remaining in current state; P1, probability of transitioning to next, more severe state; PD, probability of death. 
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patients treated with donepezil upon reaching mild–moderate 
Alzheimer’s disease; cohort 2 (predementia state with DMT), 
patients treated with a hypothetical DMT initiated in the 
predementia state; and cohort 3 (mild–moderate state DMT), 
patients treated with a hypothetical DMT upon reaching mild 
Alzheimer’s disease but not before. In addition, each model 
had three per-patient and cumulative primary endpoints: time 
spent in each of the four disease states (predementia, mild, 
moderate, and severe Alzheimer’s disease); time spent living 
in a community/home setting versus time spent in long-term 
care, defined as a skilled nursing facility, nursing home, or 
hospital/hospice; and total life-years gained.
Outcomes
While in each state, patients could either enter long-term care 
or remain in the community, based on risk. The risk for entry 
into long-term care was defined as a function of age and disease 
state, based on the published literature17 (ie, the risk of placement 
into long-term care increases with age and disease severity). 
For example, risk of placement in long-term care was much 
higher (86%) in severe Alzheimer’s disease compared with 
mild–moderate Alzheimer’s disease (17%).17 The time in each 
disease state (predementia, mild, moderate, moderately severe, 
or severe) was computed. The design of the outcome model 
within each disease state is shown in Figure 2.
Death
Mortality used in the model was based on all-cause 
  mortality, according to published data from the United 
States Statistical Abstract 2006.18 All patients were entered 
into the   simulation with an age of 75 years. The likelihood/
risk of death was dependent on age, gender, and the stage 
of Alzheimer’s disease.19 Older patients had an increasing 
risk of death and patients with more severe disease states in 
Alzheimer’s   disease were at greater risk of death. Compared 
with a matched cohort of men, women of equal age and 
severity of disease had less risk of death.19 The baseline risk 
used for all-cause mortality among men in this population 
rose from 3.5% (aged 75 years) to 10.3% (aged 85 years) to 
38.9% (aged 100 years). For women, the numbers employed 
were 2.5%, 8.2%, and 38.0%, respectively. The impact of 
disease severity on mortality was estimated by increasing 
the baseline mortality as a function of relative risk.   Relative 
risk estimates were derived from the work of Neumann et al.19 
For predementia and mild disease states, the relative risk 
for death used was 1.0 (risk of mortality equal to baseline 
of otherwise healthy, age-matched patients). For patients 
categorized with moderate Alzheimer’s disease, the relative 
risk used was 2.52, and for patients with severe Alzheimer’s 
disease, the relative risk used was 7.3.
Community
care
LTC PD
P1
P 0
Moderate
Moderately
severe
Cost-driving events occur:
eg, hospitalizations, visit to
accident and emergency,
primary care physician vist,
use of medications, death.
Events happen based on
historical, epidemiological data.
Death
Figure 2 intradisease state outcome details. Transition probabilities: P0, probability 
of remaining in current state; P1, probability of transitioning to next, more severe 
state; PD, probability of death.
Abbreviation: LTC, long-term care.
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Figure 3 Left panel: Markov model results showing the estimated count of patients (y axis) and time spent (x axis) with predementia or mild AD when initiating DMT 
during predementia AD (light gray line), DMT during mild–moderate AD (medium gray line), or sOC during mild–moderate AD (black line). Right panel: the cumulative 
time spent in predementia or mild AD if initiating DMT during predementia AD (light gray line), DMT during mild–moderate AD (medium gray line), or sOC during 
predementia AD (black line).
Abbreviations: AD, Alzheimer’s disease; DMT, disease-modifying therapy; sOC, standard of care.ClinicoEconomics and Outcomes Research 2011:3 submit your manuscript | www.dovepress.com
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Table 2 Average life-years in disease states for different DMT efficacies (all data in years)
DMT relative advantage DMT during predementia DMT during moderate AD SOC during moderate AD
Mild Severe Mild Severe Mild Severe
10% 3.46 2.54 3.35 2.60 3.19 2.56
20% 3.78 2.40 3.54 2.53 3.19 2.56
25% 3.96 2.32 3.65 2.49 3.19 2.56
Abbreviations: AD, Alzheimer’s disease; DMT, disease-modifying therapy; sOC, standard of care.
Figure 4 Left panel: Markov model results showing the estimated count of patients (y axis) and time spent (x axis) with moderate–severe AD when initiating DMT 
during predementia AD (light gray line), DMT during mild–moderate AD (medium gray line), or sOC during mild–moderate AD (black line). Right panel: the cumulative 
time spent in moderate or severe AD if initiating DMT during predementia AD (light gray line), DMT during mild–moderate AD (medium gray line), or sOC during 
predementia AD (black line).
Abbreviations: AD, Alzheimer’s disease; DMT, disease-modifying therapy; sOC, standard of care.
Impact of disease modification  
on disease progression
Finally, the impact of disease modification on disease pro-
gression was estimated in the three cohorts under each sce-
nario, ie, standard of care (treatment with donepezil   during 
mild–moderate disease), treatment during predementia 
Alzheimer’s disease with DMT, and treatment during mild–
moderate disease with DMT. As a baseline, it was assumed 
that the standard of care had no impact on the underlying 
course of disease. Transition probabilities were then based 
on the natural progression of disease.15 The relative effec-
tiveness of the potential DMT was then allowed to range 
from 10% to 30% superior to the natural course of disease. 
For example, if a DMT had a 10% superiority, the program 
reduced the annual rates of progression by 10% (ie, if pro-
gression from mild to moderate Alzheimer’s disease were 
assumed to be 20% in the natural course, a 10% superiority 
reduced the progression rate from 20% to 18%).
Results and discussion
This is the first analysis to explore the potential impact 
of early intervention with DMTs on the progression and 
outcomes of Alzheimer’s disease. This Markov model 
evaluation of the impact of early intervention with DMTs 
in patients with Alzheimer’s disease demonstrated that 
under all scenarios there was a modest advantage in life-
years gained for a hypothetical DMT (Figures 3–5). The 
presumed relative efficacy for these plots was 25% (ie, 
25% reduction in progression rates over the standard of 
care). Assuming that the availability of such an agent to 
the population could successfully slow the progression 
of disease, this analysis suggests that patients would gain 
an average of slightly less than one year of life. This is 
largely due to the reduced risk of mortality in milder 
versus more severe disease. As patients avoided more 
severe states, their risk of death related to Alzheimer’s 
disease decreased. However, patients in the model were 
assumed to enter with an age of 75 years. This relatively 
elderly age at entry has a significant impact on estimated 
  longevity, even in a healthy population. In addition, because 
earlier intervention with DMTs arrests the progression of 
disease sooner, patients in the model receiving treatment 
in the predementia Alzheimer’s stage had a slightly longer 
life expectancy than those who waited for therapy until 
affected by moderate disease.ClinicoEconomics and Outcomes Research 2011:3 submit your manuscript | www.dovepress.com
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Table 3 Life-years in the community (home) versus in long-term care for different DMT efficacies (all data in years)
DMT relative advantage DMT during predementia DMT during moderate AD SOC during moderate AD
Home LTC Home LTC Home  LTC
10% 4.87 1.13 4.79 1.16 4.44 1.30
20% 5.16 1.02 4.99 1.08 4.44 1.30
25% 5.37 0.90 5.10 1.04 4.44 1.30
Abbreviations: AD, Alzheimer’s disease; DMT, disease-modifying therapy; LTC, long-term care; sOC, standard of care.
The strongest finding of this exercise was that, while 
there was a modest benefit in total life-years gained by 
treating earlier, the distribution of these years skewed 
towards milder disease (Figures 3–5). As shown in Figures 3 
and 4 and Table 2, from our model, we found that treating 
predementia Alzheimer’s patients with DMTs increased 
life-years in the predementia to mild Alzheimer’s disease 
states on average from 3.2 years (under standard of care) 
to 4.0 years (following DMT), while life-years spent in 
moderate to severe Alzheimer’s disease decreased from 2.6 
to 2.3 years. This suggests that patients using a DMT with 
an efficacy of only 25% greater than the current standard of 
care (eg, patients treated with donepezil upon reaching mild 
Alzheimer’s disease) can expect a gain of almost 10 months 
in time spent in milder disease. This also suggests that with 
increasing efficacy of DMT treatment above this level, it is 
likely that even greater benefit in terms of time in a milder 
disease state as well as more relief from moderate to severe 
disease will be achieved. Also, because patients entered the 
simulation at 75 years of age, natural mortality is likely to 
have blunted the benefit of early DMT. Regarding younger 
patients, it is possible that these results will be even more 
pronounced given that fewer of the younger, relatively 
healthier patients die of causes potentially unrelated to 
Alzheimer’s disease.
Our model also revealed that, in addition to the gain in time 
spent in milder disease, patients with early intervention who 
were treated with an effective DMT were able to remain at 
home longer and avoid long-term care compared with patients 
who receive the standard of care (Figures 6 and 7). The average 
time remaining in the community increased from 4.4 to 5.4 
years, while time in long-term care decreased from 1.3 to 0.9 
years. This impact grew larger as the advantage of the DMT 
increased (Table 3). Thus, as the effectiveness of the drug 
increased, the overall survival of the patients was increased 
marginally. However, the balance of time that patients are able 
to remain at home and out of long-term care was increased, and 
the amount of time spent living in long-term care decreased. 
Additionally, because placement in long-term care is a func-
tion of disease state and age, earlier intervention in younger 
Figure 5 Estimated patient count (y axis) and time of death (x axis) for patients initiating DMT during predementia AD (light gray line), DMT during mild–moderate AD 
(medium gray line), or sOC during mild–moderate AD (black line).
Abbreviations: AD, Alzheimer’s disease; DMT, disease-modifying therapy; sOC, standard of care.ClinicoEconomics and Outcomes Research 2011:3 submit your manuscript | www.dovepress.com
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Figure 7 Estimated count of patients (y axis) and time spent (x axis) in long-term care if initiating DMT during predementia AD (light gray line), mild–moderate AD (medium 
gray line), or sOC during predementia AD (black line). Right panel: the cumulative time spent in long-term care if initiating DMT during predementia (light gray line), DMT 
during mild–moderate AD (medium gray line), or sOC during mild–moderate AD (black line).
Abbreviations: AD, Alzheimer’s disease; DMT, disease-modifying therapy; sOC, standard of care.
Figure 6 Estimated patient count (y axis) and time spent (x axis) in the community if initiating DMT during predementia AD (light gray line), DMT during mild–moderate AD 
(medium gray line), or sOC during mild–moderate AD (black line). Right panel: the cumulative time spent in the community if initiating DMT during predementia AD (light 
gray line), DMT during mild–moderate AD (medium gray line), or sOC during mild–moderate AD (black line).
Abbreviations: AD, Alzheimer’s disease; DMT, disease-modifying therapy; sOC, standard of care.
patients (under 75 years of age) is also likely to have an even 
more significant impact on the outcomes of interest.
Conclusion
This is the first Markov model simulation of its kind to be 
  performed examining the effect of DMT in Alzheimer’s dis-
ease. Our exercise demonstrated, not unexpectedly, that inter-
vening earlier with potential DMTs would appear to affect 
the course and outcomes of Alzheimer’s disease   significantly. 
Similar results supporting these outcomes have been seen in 
simulations generated by the Alzheimer’s Association in its 
2010 report.3
Rather than simply delaying the entry into more severe 
disease states and, ultimately, placement into long-term care, 
the impact of treatment is to reduce the time spent in these 
more severe and costly states. Therefore, with only a modest 
(efficacy 25%) impact on the course of disease progression, 
DMTs show promise for prolonging life and shifting the 
balance in favor of milder disease and more independence 
for patients with Alzheimer’s disease.
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